- Home
- XERS vs PHAR Comparison
XERS vs PHAR Comparison
Compare XERS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- PHAR
- Stock Information
- Founded
- XERS 2005
- PHAR 1988
- Country
- XERS United States
- PHAR Netherlands
- Employees
- XERS N/A
- PHAR N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- PHAR Health Care
- Exchange
- XERS Nasdaq
- PHAR Nasdaq
- Market Cap
- XERS 526.3M
- PHAR 618.3M
- IPO Year
- XERS 2018
- PHAR N/A
- Fundamental
- Price
- XERS $3.70
- PHAR $8.42
- Analyst Decision
- XERS Buy
- PHAR Strong Buy
- Analyst Count
- XERS 3
- PHAR 3
- Target Price
- XERS $4.87
- PHAR $27.00
- AVG Volume (30 Days)
- XERS 1.6M
- PHAR 5.6K
- Earning Date
- XERS 03-05-2025
- PHAR 03-13-2025
- Dividend Yield
- XERS N/A
- PHAR N/A
- EPS Growth
- XERS N/A
- PHAR N/A
- EPS
- XERS N/A
- PHAR N/A
- Revenue
- XERS $187,361,000.00
- PHAR $285,745,000.00
- Revenue This Year
- XERS $24.64
- PHAR $20.08
- Revenue Next Year
- XERS $19.04
- PHAR $9.22
- P/E Ratio
- XERS N/A
- PHAR N/A
- Revenue Growth
- XERS 22.72
- PHAR 30.64
- 52 Week Low
- XERS $1.69
- PHAR $6.65
- 52 Week High
- XERS $3.87
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- XERS 62.63
- PHAR 40.05
- Support Level
- XERS $3.47
- PHAR $7.95
- Resistance Level
- XERS $3.78
- PHAR $9.35
- Average True Range (ATR)
- XERS 0.16
- PHAR 0.52
- MACD
- XERS 0.03
- PHAR -0.16
- Stochastic Oscillator
- XERS 84.13
- PHAR 22.76
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.